Oncology FISH Analysis - Deletion 20q12 [MDS]
Use
Oncology FISH Analysis – Deletion 20q12 [MDS] is designed to detect a common chromosome deletion related to myelodysplastic syndrome (MDS), a group of cancers including acute myeloid leukemia (AML) predominantly affecting adults. The deletion 20q12 indicates a favorable prognosis and is noted in 4-5% of MDS cases. This test should be interpreted alongside relevant clinical and pathological data, and cannot be solely relied upon for an MDS diagnosis. Testing is advised for patients clinically suspected of having MDS, for the prognostic identification of anomalies, in cases where previous cytogenetic tests have failed, and for monitoring treatment responses.
Special Instructions
Results are best understood in conjunction with clinical findings and pathology data. This test is suitable for patients suspected to have myelodysplastic syndrome, serves prognostic purposes, and can be utilized if cytogenetic evaluations have failed. Continuous monitoring of treatment responses can also be conducted using this assay.
Limitations
This FISH assay specifically tests for translocations involving the AML1 and ETO loci; it cannot identify translocations with other partners outside this scope, which may limit its diagnostic completeness for certain cases.
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow (Fresh)
Volume
3-5 cc
Minimum Volume
2 cc
Container
Sodium Heparin tube
Collection Instructions
Draw bone marrow in a Sodium Heparin (green-top) tube(s) and send 3-5 cc (Adults/Children) or 2 cc (Infant< 2 years).
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Specimen should arrive in the laboratory within 48 hrs of collection. Do not heat or freeze. |
Other tests from different labs that may be relevant